Dr. Scheideler founded HumanFirst Therapeutics LLC in 2011 with the aim of identifying Therapy and Diagnostic Development Projects, and then assembling the teams, funding and management needed to progress them to the clinic. The LLC provides Advisory services and Managing Partner expertise to Disease Foundations, Universities and Companies. Key examples of HumanFirst Initiatives & Impact:• Research Direction for the Therapies for Inherited Neuropathies Foundation (TIN) since 2017. Develops, Directs and Partners projects aimed at identifying therapies for CMT Type 1 disorders. -“Man of Steel” TIN award in 2023 for impact in CMT treatment research. • Strategy Development for the Undiagnosed Diseases Network Foundation (2024), as it seeks to capture innovation of the NIH-Funded UDN consortium through external collaboration & partnering.• Research Strategy & Alliances for the Charcot-Marie-Tooth Association (2012-2024). Chair of its Therapy Expert Advisory Board. The LLC guided the formation and operation of dozens of partnerships. Association lead for research and alliance agreements, licensing & patenting. Shaped the Research Governance of the CMTA. -Established and directed landmark alliance effort with Ionis to develop antisense therapy for CMT1A. (see: J Clinical Investigation: https://www.jci.org/articles/view/96499) -Patented the first authentic animal model of a progressive CMT2A axonopathy. - CMTA STAR award in 2018 for “Passion and Commitment to the STAR Research Program”• Active advisor to University Technology Transfer funds. Expert Evaluator/Rapporteur for the EU Innovative Medicines Initiative, and Expert Adviser to the EU OpenScreen Initiative. Member of the Drug Discovery Advisory Board Member of the Myelin Repair Foundation. Partnering for Cures (Faster Cures) Expert Consultant.• Advisory services to small and medium sized businesses led to award of >$60 million in Federal Contracts and small business grants.

Developed and directed a trans-NIH Roadmap Initiative to create technologies and projects for use by the Molecular Libraries Consortium of High-Throughput Screening Centers (mli.nih.gov). Member of the Molecular Libraries Implementation Group and Operations Management Teams. Started and led Cross-Institute grant and small business Drug Optimization Programs to facilitate partnering of Biology with Chemistry expertise and leverage Chemo-Informatic outsourcing. Member of the Roadmap Clinical-Translational Science Awards Consortium Steering Committee (www.ctsa.org). Founded & coordinated the CTSA Public-Private-Partnership Committee, leading to launch of the intellectual property web-based search tool CTSA-IP (www.ctsaip.org). • NIH Directors Awards for Extraordinary Scientific Leadership of the Molecular Libraries Initiative, and also for Outstanding Contributions to the CTSA Launch.• Notable Work: CTSA-IP: A solution to identifying and aggregating intellectual property across the NIH Clinical Translational Science Award (CTSA) consortium of biomedical research institutes. Hazard M, Steele S, Wang D, Pearson T, Scheideler M, Dewhurst S. Clin Transl Sci.(2012) 5, 112.

General Manager of European site with responsibility for Biology, Analytical and Informatic operations. Led Strategic Alliance with Abgenix to co-develop therapeutic antibodies. Headed Biology operations for sites in Europe, the USA and Canada. Member of MDS Inc Business Development team that created MDS-Denmark, further acquired by Thermo-Fisher.

Repositioned Italian Biology Research organization as a Department in the Global Neurosciences organization. Proposed, implemented, led new chronic Pain Therapy Area focus. Started the first company Clinical Development Project in Neuropathic pain. Drug Discovery and Pre-Clinical Research responsibility across 4 therapy areas, leading to multiple Clinical Drug Candidates. Member, European Science Committee.

Head of Cellular & Biochemical pharmacology team. Program leader with cross-functional line responsibility. Started and led Drug Discovery & Pre-Clinical Programs in drug lead seeking, chemical optimization and Proof-of-Principle testing. Member of Pharmaceuticals Division Research Board.Participated in multiple drug candidate submissions

NIH-sponsored studies aimed at elucidating the structural requirements for receptor and ion channel function.